JCR Pharmaceuticals, Author at JCR Pharmaceuticals - Page 10 of 10

Change in duties of corporate officers, organizational and personnel changes

Hyogo, Japan – February 27, 2025 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that its Board of Directors resolved at a meeting held today to change in duties of corporate officers, organizational and personnel changes.

Download PDF below to read full announcement.

by JCR Pharmaceuticals

Notice concerning the start of construction of a new drug product plant

by JCR Pharmaceuticals

JCR Pharmaceuticals proudly supports Rare Disease Day 2025

by JCR Pharmaceuticals

Notice of partial correction to “FY2024 third quarter consolidated financial results conference call material”

by JCR Pharmaceuticals

JCR Pharmaceuticals’ research presentations at WORLDSymposium 2025 showcase research from its investigational treatments for LSDs

by JCR Pharmaceuticals

FY2024 third quarter consolidated financial results conference call scrip

February 4, 2025

FY2024 third quarter consolidated financial results conference call material

by JCR Pharmaceuticals

Revision of consolidated financial forecasts for fiscal year ended March 31, 2025

by JCR Pharmaceuticals

Financial summary consolidated financial results for the nine months ended December 31, 2024 (FY2024) (Japanese standard)

by JCR Pharmaceuticals